Summary
The disposition of many drugs in cystic fibrosis is abnormal. In general, changes in pharmacokinetics include: increased volume of distribution, decreased plasma concentration, and enhanced renal and sometimes non-renal elimination of drugs. Pathophysiology of the disease important for drug disposition includes: (a) hypersecretion of gastric acid and duodenal secretions which are of small volume, viscous and low in bicarbonate: (b) increased intestinal permeability to some sugars and probe substances; (c) hypergammaglobulinaemia and sometimes hypoalbuminaemia; (d) significant elevation of free fatty palmitoleic acid level and decreased low-density and high-density serum lipoproteins; (e) an average increase by 30 to 45% in plasma volume in patients with cystic fibrosis who have moderately severe pulmonary disease, right ventricle hypertrophy and dilatation, which occurs in 15 to 35% of patients with a Shwachman score of 81 to 100; (f) abnormal bile acid metabolism and enterohepatic recirculation; and (g) enlarged kidneys and glomerulomegaly with increased glomerular filtration rate, tubular clearance and urine flow rate in some patients with cystic fibrosis.
Delayed absorption from the gastrointestinal tract has been reported in patients with cystic fibrosis for cloxacillin, epicillin, clindamycin, ciprofloxacin and probably for cephalexin, para-aminobenzoic acid and chloramphenicol. A possible increased absorption was reported for cimetidine. Of 7 drugs studied only theophylline had significantly decreased plasma protein binding. An increased volume of distribution and increased renal clearance reported for several drugs is caused mainly by increases in plasma volume and urine flow rate in many of these patients. Possible increased elimination of some drugs in bile (which probably results from bile acid malabsorption) and in bronchial secretions (which are abundant in some cystic fibrosis patients with acute pulmonary infection) may explain enhanced non-renal elimination of these drugs. The metabolism of cimetidine in cystic fibrosis was reported not to be changed significantly compared to control subjects.
Similar content being viewed by others
References
Abman SH, Reardon MC, Accurso FJ, Hammond KB, Sokol RJ. Hypoalbuminemia at diagnosis as a marker for severe respiration course in infants with cystic fibrosis identified by newborn screening. Journal of Pediatrics 107: 933–935, 1985
Abramowsky CR, Swinehart GL. The nephropathy of cystic fibrosis: a human model of chronic nephrotoxicity. Human Pathology 13: 934–939, 1982
Agnihotri S, Clark R, Cooper S. Chronic pulmonary disease and antipyrene disposition. British Journal of Clinical Pharmacology 5: 275–277, 1978
Aladjem M, Lotan D, Boichis H, Orda S, Katznelson D. Renal function in patients with cystic fibrosis. Nephron 34: 84–86, 1983
Alexander MR, Schoell J, Hicklin G, Coleman D. Bronchial secretion concentrations of tobramycin. American Reviews of Respiratory Diseases 125: 208–209, 1982
Arvidsson A, Alvan G, Angelin B, Borga O, Nord CE. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. Journal of Antimicrobial Chemotherapy 10: 207–215, 1982
Arvidsson A, Alvan A, Strandvik B. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects. Acta Paediatrica Scandinavica 72: 293–294, 1983
Avery GS (Ed.). Drug treatment: principles and practice of clinical pharmacology and therapeutics, 2nd ed., ADIS Press, Sydney and New York, 1980
Balant L, Dayer P, Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clinical Pharmacokinetics 10: 101–143, 1985
Bennet CM, Brenner BM, Berliner RW. Micropuncture study of nephron function in the rhesus monkey. Journal of Clinical Investigation 47: 203–216, 1968
Berg U, Kusoffsky E, Strandvik B. Renal function in cystic fibrosis with special reference to the renal sodium handling. Acta Paediatrica Scandinavica 71: 833–838, 1982
Bergan T. Overview of acylureidopenicillin pharmacokinetics. Scandinavian Journal of Infectious Diseases (Suppl. 29): 33–48, 1981
Bergan T, Michaisen H. Pharmacokinetics of azlocillin in children with cystic fibrosis. Drug Research 29: 1955–1957, 1979
Blumer JL, Stern RC, Klinger JD, Yamashita TS, Meyer CM, et al. Ceftazidime therapy in patients with cystic fibrosis and multiple-drug-resistant Pseudomonas. American Journal of Medicine 79(Suppl. 2A): 37–46, 1985
Blumer JL, Stern RC, Yamashita TS, Myers CM, Reed MD. Cephalosporin therapeutics in cystic fibrosis. Journal of Pediatrics 108: 854–860, 1986
Boat T, Doershuk C, Stern R, Matthews L. Serum alkaline phosphatase in cystic fibrosis. Clinical Pediatrics 13: 505–512, 1974
Bodemar G, Norlander B, Walan A. Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clinical Pharmacokinetics 6: 306–315, 1981
Bosso JA, Saxon BA, Herbst JJ, Matsen JM. Azlocillin pharmacokinetics in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 25: 630–632, 1984
Bosso JA, Townsend PL, Herbst JJ, Matsen JM. Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 28: 829–831, 1985
Bradbear RA, Shepherd RW, McGuffie C, Grice J, Roberts RK. The kinetics of oral cimetidine in children with cystic fibrosis. British Journal of Clinical Pharmacology 12: 248–249, 1981
Brenner BM, Berliner RW. Relationship between extracellular volume and fluid reabsorption by the rat nephron. American Journal of Physiology 217: 6–12, 1969
Brittain DC, Scully BE, McElrath C, Steinman R, Labthavikul P, et al. The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. Journal of Clinical Pharmacology 25: 82–88, 1985
Brown JE, DelBene VE, Collins CD. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance. Antimicrobial Agents and Chemotherapy 19: 248–252, 1981
Brown RD, Manno JE. ESTRIP and BASIC computer program for obtaining initial polyexponential parameter estimates. Journal of Pharmaceutical Sciences 67: 1687–1691, 1978
Burgi H, Wiesmann U, Richterich R, Regli J, Medici T. New objective criteria for inflammation in bronchial secretions. British Medical Journal 2: 654–656, 1968
Buts JP, Morin CL, Roy CC, Weber A, Bonin A. One-hour blood xylose test: a reliable index of small bowel function. Journal of Pediatrics 92: 729–733, 1978
Cantor P, Garne S, Rehfeld JF. Cholecystokinin and cystic fibrosis. Lancet 2: 1039, 1984
Caplan A, Gross S. Hematologic and serologic studies in cystic fibrosis. Journal of Pediatrics 73: 540–547, 1968
Carbon C, Dromer F, Brian N, Cremieux AC, Contrepois A. Renal tubular handling of ceftazidime illustrated by drug interference. Proceedings of the Second World Conference on Clinical Pharmacology, Washington, D.C., July 31–August 5, Abstract no. 638, 1983
Caren R, Corbo L. Plasma fatty acids in pancreatic cystic fibrosis and liver disease. Journal of Clinical Endocrinology 26: 470–477, 1966
Clissold SP, Todd PA, Campoli-Richards DM. Imipenem/Cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 33: 183–241, 1987
Cornish H, Cristman A. Study of the metabolism of theobromide, theophylline and caffeine in man. Journal of Biological Chemistry 228: 315–323, 1957
Cox KL, Isenberg JN. Hypersecretion of gastric acid in patients with pancreatic exocrine insufficiency due to cystic fibrosis (Abstract). Gastroenterology 74: 1022, 1978
Cox KL, Isenberg JN, Ament ME. Gastric acid hypersecretion in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1: 559–565, 1982
Cox KL, Isenberg JN, Osher AB, Dooley RR. The effects of cimetidine on maldigestion in cystic fibrosis. Journal of Pediatrics 94: 488–492, 1979
Craig M, Haddad H, Shwachman H. The pathological changes in the liver in cystic fibrosis. American Journal of Diseases of Children 93: 357–369, 1957
Davis BE, Humphrey MJ, Langley PF, Lees L, Legg B, et al. Pharmacokinetics of ticarcillin in man. European Journal of Clinical Pharmacology 23: 167–172, 1982
Dickinson CJ, Aronoff SC, Stern RC, Reed MD, Blumer JL. Modulation of chloramphenicol (C) bioavailability by pancreatic enzymes replacement (PER) in cystic fibrosis. Pediatric Research 18: 151A, 1984
DiSant’Agnese PA, Talamo RC. Pathogenesis and physiopathology of cystic fibrosis of the pancreas: fibrocystic disease of the pancreas. New England Journal of Medicine 277: 1399–1408, 1967
Dittert LW, Griffen WO, La Piana JC. Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration. Antimicrobial Agents and Chemotherapy 9: 42–48, 1969
Doershuk CF, Boat TF. Cystic fibrosis. In Behrman et al. (Eds) Nelson textbook of pediatrics, p. 1094, WB Saunders Co., Philadelphia, 1983
Drug Information for the Health Care Provider, 6th ed., USPDI®, USP Convention Inc., Rockville, 1986
du Swich P, Lalka D, Slaughter R, Elvin AT, McLean AJ. Mechanisms of nonlinear disposition kinetics of sulfamethazine. Clinical Pharmacology and Therapeutics 25: 172–183, 1979
Finkelstein E, Hall K. Aminoglycoside clearance in patients with cystic fibrosis. Journal of Pediatrics 94: 163–164, 1979
Fondacaro JD, Heubi JE, Kellog FW. Intestinal bile acid malabsorption in cystic fibrosis: a primary mucosal cell defect. Pediatric Research 16: 494–498, 1982
Frase LL, Strickland AD, Kachel GW, Krejs GJ. Enhanced glucose absorption in the jejunum of patients with cystic fibrosis. Gastroenterology 88: 478–484, 1985
Freye H, Kurtz S, Spöck A, Capp M. Light and electron microscopic examination of the small bowel of children with cystic fibrosis. Journal of Pediatrics 64: 575–579, 1964
Gal P, Jusko WH, Yurchak AM. Theophylline disposition in obesity. Clinical Pharmacology and Therapeutics 23: 438–444, 1978
Ganong WF. Review of medical physiology, 12th ed., Lange Medical Publications, Los Altos, Ca., 1985
Garret ER. Pharmacokinetics and clearances related to renal processes. International Journal of Clinical Pharmacology 16: 155–172, 1978
Georgitis JW, Eigen H, Warner R, Gonzales MA. Oral theophylline disposition in cystic fibrosis. Annals of Allergy 48: 175–177, 1982
Gibson RA, Teubner JK, Haines K, Cooper DM, Davidson GP. Relationship between pulmonary function and plasma fatty acid levels in cystic fibrosis patients. Journal of Pediatric Gastroenterology and Nutrition 5: 408–415, 1986
Goldfarb J, Worniser GP, Inchiosa MA, Guideri G, Diaz M, et al. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. Journal of Clinical Pharmacology 26: 222–226, 1986
Gonzales MA, Uribe F, Moisen SD, Welling PG, Painter B. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrobial Agents and Chemotherapy 26: 741–744, 1984
Goodchild M, Murphy G, Howell A, Nutter S, Andersen CM. Aspects of bile acid metabolism in cystic fibrosis. Archives of Diseases of Childhood 50: 769–778, 1975
Gosden CM, Gosden JR. Fetal abnormalities in cystic fibrosis suggest a deficiency in proteolysis of cholecystokinin. Lancet 2: 541–546, 1984
Grahnén A, von Bahr C, Lindström B, Rosén A. Bioavailability and pharmacokinetics of cimetidine. European Journal of Clinical Pharmacology 16: 335–340, 1979
Grand R, Lebenthal E, Jacobson M. Predictive value of BSP kinetics for early liver involvement in cystic fibrosis. Proceedings of the 7th International Congress on Cystic Fibrosis, Paris, Boehringer Mannheim, pp. 463–467, 1978
Green MN, Kulczycki LL, Shwachman H. Serum protein paper electrophoresis in patients with cystic fibrosis. American Journal of Diseases of Children 100: 365–372, 1960
Gryboski JD, Thayer WR, Gabrielson IW, Spiro HM. Disacchariduria in gastrointestinal disease. Gastroenterology 45: 633–637, 1963
Grygiel J, Birkitt D. Effect of age on patterns of theophylline metabolism. Clinical Pharmacology and Therapeutics 28: 456–462, 1980
Guggenbichler JP, Kienel G. Bioavailability of oral antibiotics in cystic fibrosis. Monographia Paediatrica 10: 34–40, 1979
Gugler R, Somogyi A, Bergman K. The biliary excretion of histamine H2-receptor antagonists cimetidine and oximetidine. Clinical Pharmacology and Therapeutics 29: 249, 1981
Hadorn B, Zoppi G, Shmerling D, Prader A, McIntyre I, et al. Quantitative assessment of exocrine pancreatic function in infants and children. Journal of Pediatrics 73: 39–50, 1968
Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneels R, et al. Should clearance be normalised to body surface or to lean body mass? British Journal of Clinical Pharmacology 11: 523–525, 1981
Halvorsen L, Dotevall G, Walan A. Gastric emptying in patients with achlorhydria or hyposecretion of hydrochloric acid. Scandinavian Journal of Gastroenterology 8: 395–399, 1973
Harrison CJ, Marks MI, Welch DF, Sharma BB, Baker D, et al. A multicenter comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to young children with cystic fibrosis. Pediatric Pharmacology 5: 7–16, 1985
Hendeles L, Iafrate RP, Stillwell PC, Mangos JA. Individualizing gentamicin dosage in patients with cystic fibrosis: limitations to pharmacokinetic approach. Journal of Pediatrics 111: 303–310, 1987
Hendeles L, Weinberger M, Johnson G. Theophylline. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, pp. 95–138, Applied Therapeutics Inc., San Francisco, 1980
Houdret N, Perini JM, Galabert C, Scharfman A, Humbert P, et al. The high lipid content of respiratory mucins in cystic fibrosis is related to infection. Biochemica et Biophysica Acta 880: 54–61, 1986
Hsu MCJ, Aguila HA, Schmidt VL, Munzenberger PJ, Kauffman RE, et al. Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatric Infectious Diseases 3: 526–529, 1984
Huang NN, Hiller EJ, Macri CM, Capitanio M, Cundy KR. Carbenicillin in patients with cystic fibrosis: clinical pharmacology and therapeutic evaluation. Journal of Pediatrics 78: 338–345, 1971
Isles AF, Spino M, Tabachnik E, Levison H, Thiessen JJ, et al. Theophylline disposition in cystic fibrosis. American Reviews of Respiratory Diseases 127: 417–421, 1983
Jacobs RF, Trang JM, Kearns GL, Warren RH, Brown AL, et al. Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. Journal of Pediatrics 106: 1001–1007, 1985
Jahre JA, Ku FP, Neu HC. Kinetics of netilmicin and gentamicin. Clinical Pharmacology and Therapeutics 23: 591–597, 1978
Jansen JBMJ, Jongerius CM, Lamers CBHW. Cholecystokinin and cystic fibrosis. Lancet 1: 58, 1985
Jusko WJ, Mosovich LL, Gerbracht LM, Mattar ME, Yaffe SJ. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics 56: 1038–1044, 1975
Kaplan SA, Weinfeld RE, Abruzzo CW, McFaden K, Jack ML, et al. Pharmacokinetic profile of trimethoprim-sulfamethoxazole in man. Journal of Infectious Diseases 128 (Suppl.): S547, 1973
Kattwinkel J, Taussing LM, Statland BE, Verter JI. The effect of age on alkaline phosphatase and other serologic liver function tests in normal subjects and patients with cystic fibrosis. Journal of Pediatrics 82: 234–242, 1973
Kearns GL, Hilman BC, Wilson JT. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. Journal of Pediatrics 100: 312–318, 1982
Kearns GL, Trang JM. Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype. Journal of Pediatrics 108: 847–852, 1986
Kedem O, Katchalsky A. Thermodynamic analysis of the permeability of biological membranes to non-electrolytes. Biochemica et Biophysica Acta 27: 229–246, 1958
Kelly HB, Menendez R, Fan L, Murphy S. Pharmacokinetics of tobramycin in cystic fibrosis. Journal of Pediatrics 100: 318–321, 1982
Kelly HW, Lovato C. Antibiotic use in cystic fibrosis. Drug Intelligence and Clinical Pharmacy 18: 772–783, 1984
Kercsmar CM, Stern RC, Reed MD, Myers CM, Merdell D, et al. Ceftazidime in cystic fibrosis: pharmacokinetic and therapeutic response. Journal of Antimicrobial Chemotherapy 12(Suppl. A): 289–295, 1983
Knox FG, Cuche JL, Ott CE, Diaz-Buzo JA, Marchand G. Regulation of glomerular filtration and proximal tubule reabsorption. Circulation Research 36(Suppl. 1): 107–118, 1975
Komiya I. Urine flow dependence on renal clearance and interrelation of renal reabsorption and physicochemical properties of drugs. Drug Metabolism and Disposition 14: 239–245, 1986
Koren G, Weizman Z, Forstner G, MacLeod SM, Durie PR. Altered PABA pharmacokinetics in cystic fibrosis: implications for bentromide test. Digestive Diseases and Sciences 30: 928–932, 1985
Koushanpour E. Renal physiology: principles and function, WB Saunders, Philadelphia, 1976
Kuo PT, Huang NN. Effect of medium chain triglyceride upon fat absorption and plasma lipid and depot fat of children with cystic fibrosis of pancreas. Journal of Clinical Investigation 44: 1924–1933, 1965
Larsen GL, Barron RJ, Landay RA, Cotton EK, Gonzales MA, et al. Intravenous aminophylline in patients with cystic fibrosis: pharmacokinetics and effect on pulmonary function. American Journal of Diseases of Children 134: 1143–1147, 1980
Lau WK, Young LS, Osher AB, Dooley RR. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Pediatrics 60: 372–377, 1977
LeBel M, Bergeron MG, Vallée F, Fiset C, Chassé G, et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 30: 260–266, 1986
Leclercq-Foucart J, Forget P, Sodoyez-Goffaux F, Zapitelli A. Intestinal permeability to (51Cr)EDTA in children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 5: 384–387, 1986
Leeder JS, Spino M, Isles AF, Tesoro AM, Gold R, et al. Cef tazidime disposition in acute and stable cystic fibrosis. Clinical Pharmacology and Therapeutics 36: 355–362, 1984
Lentner C (Ed.). Geigy scientific tables. Vol. 1, Ciba-Geigy Ltd, Basel, 1981
Lesko LJ. Dose-dependent elimination kinetics of theophylline. Clinical Pharmacokinetics 4: 449–459, 1979
Lester LA, Egge AC, Hubbard VS, Camerini-Otero CS, Fink RJ. Echocardiography in cystic fibrosis: a proposed scoring system. Journal of Pediatrics 97: 742–748, 1980
Levinsky NG. Nonaldosterone influence on renal sodium transport. Annals of New York Academy of Sciences 139: 295–303, 1966
Levy G, Koysooko R. Renal clearance of theophylline in man. Journal of Clinical Pharmacology 6: 329–332, 1976
Levy J. Antibiotic activity in sputum. Journal of Pediatrics 108: 841–846, 1986
Levy J, Smith AL, Kenny MA, Ramsey B, Schoenknecht FD. Gentamicin bioactivity in purulent sputum from patients with cystic fibrosis and bronchiectasis: comparison with serum. Journal of Infectious Diseases 148: 1069–1076, 1983
Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. Journal of Pediatrics 105: 117–124, 1984
Lopez-Vidriero MT, Reid L. Bronchial mucins in health and disease. British Medical Bulletin 34: 63–74, 1978
MacDonald NE, Anas NG, Peterson RG, Schwartz RH, Brooks JG, et al. Renal clearance of gentamicin in cystic fibrosis. Journal of Pediatrics 103: 985–990, 1983
MacLusky I, McLaughlin FJ, Levison H. Cystic fibrosis: part I and II. Current Problems in Pediatrics 15: no. 6, pp. 1–49; no. 7, pp. 1–39, 1985
Marks MI. Treatment of cystic fibrosis with trimethoprim-sulfamethoxazol. Correspondence. Journal of Pediatrics 105: 679–680, 1984
Marks MI, Vose A, Hammerberg S, Dugal R. Clinico-pharmacological studies of sisomicin in ill children. Antimicrobial Agents and Chemotherapy 13: 753–758, 1978
McCrae WM, Raeburn JA, Hanson EJ. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum. Journal of Infectious Diseases 134: 1915–1918, 1976
Mearns MB. Cystic fibrosis. Archives of Diseases of Childhood 60: 272–277, 1985
Michaisen H, Bergan T. Pharmacokinetics of netilmicin in children with and without cystic fibrosis. Antimicrobial Agents and Chemotherapy 19: 1029–1031, 1981
Michaisen H, Bergan T. Pharmacokinetics of antibiotics in children with cystic fibrosis with particular reference to netilmicin. Acta Paediatrica Scandinavica 301 (Suppl.): 101–105, 1982
Michaisen H, Bergan T. Pharmacokinetics of azlocillin in children with and without cystic fibrosis treated for infectious diseases. Methods and Findings in Experimental and Clinical Pharmacology 8: 727–729, 1986
Michaisen H, Bergan T, Solberg R. Pharmacokinetic evaluation of cefsulodin in children with and without cystic fibrosis treated for infectious diseases. Methods and Findings in Experimental and Clinical Pharmacology 8: 685–687, 1986
Michaisen H, Monn E, Bergan T, Churgand J, Johannessen JV. Renal biopsies in cystic fibrosis. Pathology Research in Practice 178: 261–267, 1984
Milla P, Rassam U, Kilby A. Small intestinal absorption of amino acids and dipeptide in pancreatic insufficiency. In Sturgess (Ed.) Perspectives in cystic fibrosis, pp. 177–180, Canadian Cystic Fibrosis Foundation, Toronto, 1980
Morin C, Roy C, Lasalle R, Bonin A. Small bowel mucosal dysfunction in patients with cystic fibrosis. Journal of Pediatrics 88: 213–216, 1976
Moss AJ. The cardiovascular system in cystic fibrosis. Pediatrics 70: 728–741, 1982
Moss AJ, Finkelstein S, Crudup C, Young GA, Dooley RR, et al. Absorption of digoxin in children with cystic fibrosis. Journal of Pediatrics 86: 295–297, 1975
Mudge GH, Silva P, Stibitz GR. Renal excretion by non-ionic diffusion: the nature of the disequilibrium. Medical Clinics of North America 59: 681–698, 1975
Nahata MC, Lubin AH, Visconti JA. Cephalexin pharmacokinetics in patients with cystic fibrosis. Developmental Pharmacology and Therapeutics 7: 221–228, 1984
Nelson J. Antimicrobial drugs. In Yaffe (Ed.) Pediatric pharmacology: therapeutic principles in practice, p. 173, Grune and Stratton Inc., New York, 1980
Norrby SR, Alestig K, Ferber F, Huber JL, Jones KH, et al. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK 0787) in humans. Antimicrobial Agents and Chemotherapy 23: 293–299, 1983
Padoan R, Brienza A, Crossignani RM, Lodi G, Giunta A, et al. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Journal of Pediatrics 103: 320–324, 1983
Paisley JW, Washington JA. Combined activity of clavulanic acid and ticarcillin against ticarcillin-resistant, gram-negative bacilli. Antimicrobial Agents and Chemotherapy 14: 224–227, 1978
Park RW, Grand RJ. Gastrointestinal manifestations of cystic fibrosis: a review. Gastroenterology 81: 1143–1161, 1981
Parsons RL, Paddock M. Absorption of two antibacterial drugs, cephalexin and co-trimoxazole, in malabsorption syndromes. Journal of Antimicrobial Chemotherapy 1 (Suppl.): 59–67, 1975
Patel RB, Welling PG. Clinical pharmacokinetics of co-trimoxazole. Clinical Pharmacokinetics 5: 405–423, 1980
Pechere JC, Dugal R. Clinical pharmacokinetics of aminoglycoside antibiotics. Clinical Pharmacokinetics 4: 170–199, 1979
Pechere JC, Dugal R, Pechere MM. Kinetics of netilmicin and gentamicin in man. Clinical Pharmacology and Therapeutics 23: 677–684, 1978
Pedersen PV, Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. Journal of Pharmaceutical Sciences 69: 394–398, 1980
Pennington JE. Penetration of antibiotics into respiratory secretions. Reviews of Infectious Diseases 3: 67–73, 1981
Permin H, Koch C, Hoiby N, Christensen HO, Moller AF, et al. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 12(Suppl. A): 313–323, 1983
Pitt HA, Roberts RB, Johnson Jr WD. Gentamicin levels in human biliary tract. Journal of Infectious Diseases 127: 299–302, 1973
Prandota J. Clinical pharmacokinetics of changes in drug elimination in children. Developmental Pharmacology and Therapeutics 8: 311–328, 1985
Prandota J. Drug disposition in cystic fibrosis. Progress in understanding pathophysiology and pharmacokinetics. Pediatric Infectious Disease 6: 1111–1126, 1987
Prandota J, Smith IJ, Wilson JT. Dosage regimen of cimetidine revisited: possible accumulation of the drug after multiple oral doses. European Journal of Clinical Pharmacology, in press, 1988
Prandota J, Witkowska M. Pharmacokinetics and metabolism of furosemide in man. European Journal of Drug Metabolism and Pharmacokinetics 1: 177–181, 1976
Prince AS, Neu HC. Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. Journal of Pediatrics 97: 148–151, 1980
Raeburn JA, Devine JD. Clindamycin in sputum in a patient with purulent chest disease due to cystic fibrosis. Postgraduate Medical Journal 47: 366–367, 1971
Rector FC, Van Giesen G, Kiil F, Seidin DW. Influence of expansion of extracellular volume on tubular reabsorption of sodium independent of changes in glomerular filtration rate and aldosterone activity. Journal of Clinical Investigation 43: 341–348, 1964
Reed MD, Stern RC, Bertino Jr JS, Myers CM, Yamashita TS, et al. Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. Journal of Pediatrics 104: 303–307, 1984a
Reed MD, Stern RC, O’Brien CA, Yamashita TS, Myers CM, et al. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 27: 583–588, 1985
Reed MD, Stern RC, Yamashita TS, Ackers I, Myers CM, et al. Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 25: 579–581, 1984b
Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 27: 469–527, 1984
Riff LJ, Moreschi G. Netilmicin and gentamicin: comparative pharmacology in humans. Antimicrobial Agents and Chemotherapy 11: 609–614, 1977
Robson AM, Tateishi S, Ingelfinger JR, Strominger DB, Klahr S. Renal function in patients with cystic fibrosis. Journal of Pediatrics 79: 42–50, 1971
Rosenblatt JE, Kuid AC, Brodie JL, Kirby WMM. Mechanisms responsible for the blood level differences of isoxazolyl penicillins. Archives of Internal Medicine 121: 345–348, 1968
Rosenthal A, Button LN, Khaw KT. Blood volume changes in patients with cystic fibrosis. Pediatrics 59: 588–594, 1977
Schentag JJ. Aminoglycosides. In Evans et al. (Eds) Applied pharmacokinetics, pp. 174–209, Applied Therapeutics Inc., San Francisco, 1980
Schröder H, Gilbert RD, Power GG. Urinary and hemodynamic responses to blood volume changes in fetal sheep. Journal of Developmental Physiology 6: 131–141, 1984
Schwartz RH. Serum immunoglobulin levels in cystic fibrosis. American Journal of Diseases of Children 111: 408–411, 1960
Shapiro GG, Bamman J, Kanarek P, Bierman CW. The paradoxical effect of adrenergic and methylxanthine drugs in cystic fibrosis. Pediatrics 58: 740–743, 1976
Shwachman H, Kulczycki LL. Long term study of 105 patients with cystic fibrosis: studies made over a 5- to 14-year period. American Journal of Diseases of Children 96: 6–15, 1958
Siber GR, Smith AL, Levin MJ. Predictability of peak serum gentamicin concentration with dosage based on body surface area. Journal of Pediatrics 94: 135–143, 1979
Sirota JH, Baldwin DS, Villarreal H. Diurnal variations of renal function in man. Journal of Clinical Investigation 29: 187–192, 1950
Smith AL. Antibiotic therapy in cystic fibrosis: evaluation of clinical trials. Journal of Pediatrics 108: 866–870, 1986
Somogyi A, Becker M, Gugler R. Cimetidine pharmacokinetics and dosage requirements in children. European Journal of Pediatrics 144: 72–76, 1985
Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clinical Pharmacokinetics 8: 463–495, 1983
Spence RW, Celestin LR, De la Guardia R. Biliary secretion of cimetidine in man. In Burland et al. (Eds) Proceedings of the second international symposium on histamine H2-receptor antagonists, pp. 81–86, Excerpta Medica, Amsterdam, 1977
Spino M, Chai RP, Isles AF, Balfe JW, Brown RG, et al. Assessment of glomerular filtration rate and effective renal plasma flow in cystic fibrosis. Journal of Pediatrics 107: 64–70, 1985
Spino M, Chai RP, Isles AF, Thiessen JJ, Tesoro A, et al. Cloxacillin absorption and disposition in cystic fibrosis. Journal of Pediatrics 105: 829–835, 1984
Sproul A, Huang N. Growth patterns in children with cystic fibrosis. Journal of Pediatrics 65: 664–674, 1964
Stoeckel K. Pharmacokinetics of Rocephin®, a highly active new cephalosporin with an exceptionally long biological half-life. Chemotherapy 27(Suppl. 1): 42–46, 1981
Strandvik B, Malmorg AS, Alfredson H, Ericsson A. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 12(Suppl. A): 283–287, 1983
Strober W, Peter G, Schwartz RH. Albumin metabolism in cystic fibrosis. Pediatrics 43: 416–426, 1969
Tang-Liu DDS, Tozer TN, Riegelman S. Urine flow dependence of theophylline renal clearance in man. Journal of Pharmacokinetics and Biopharmaceutics 10: 351–364, 1982
Tang-Liu DDS, Tozer TN, Riegelman S. Dependence of renal clearance on urine flow: a mathematical model and its application. Journal of Pharmaceutical Sciences 72: 154–158, 1983
Taussig LM, Kattwinkel J, di Sant’Agnese PA. A new prognostic score and clinical evaluation system for cystic fibrosis. Journal of Pediatrics 82: 380–390, 1973
Taylor DC, Cresswcll PR, Bartlett DC. The metabolism and elimination of cimetidine, a histamine H2-reccplor antagonist, in the rat, dog and man. Drug Disposition Metabolism 6: 21–30, 1978
Thys JP, Monawad E, Klastcrsky J. Concentrations of netilmicin in bronchial secretions and scrum during intermittent vs continuous infusion: a crossover study in humans. Journal of Infectious Diseases 140: 634, 1979
Valman HB, Evans KE. Serum unbound levels of cloxacillin and erythromycin in cystic fibrosis. Archives of Diseases of Childhood 45: 686–689, 1970
Van Caillie-Bertrand M, DeBieville F, Neijens H. Trace metals in cystic fibrosis. Acta Paediatrica Scandinavica 71: 203–207, 1982
Vaughan W, Lindgren F, Whalen J, Abrahams S. Serum lipoprotein concentrations in cystic fibrosis. Science 199: 783–786, 1978
Vawter GF, Shwachman H. Cystic fibrosis in adults: an autopsy study. Pathology Annual 14: 357–382, 1979
Vieira FL, Malnic G. Hydrogen ion secretion by rat cortical tubules as studied by an antimony microelectrode. American Journal of Physiology 214: 710–718, 1968
Vogelstein B, Kowarski AA, Lielman PS. The pharmacokinetics of amikacin in children. Journal of Pediatrics 91: 333–339, 1977
Wainwright BJ, Scambler PJ, Schmidtke J, Watson EA, Law H-Y, et al. Localization of cystic fibrosis locus to human chromosome 7 cen-q22. Nature 318: 384–385, 1985
Walkenstein SS, Dubb JW, Randolph WC, Wcstlake WJ, Stole RM, et al. Bioavailability of cimetidine in man. Gastroenterology 74: 360–365, 1978
Watkins J, Tercyak AM, Szczepanik P, Klein PD. Bile salt kinetics in cystic fibrosis: influence of pancreatic enzyme replacement. Gastroenterology 73: 1023–1028, 1977
Weber A, Roy C, Charlrand L, Lepage G, Dufour OL, et al. Relationship between bile acid malabsorption and pancreatic insufficiency of cystic fibrosis. Gut 17: 295–299, 1976
Weber A, Roy C, Morin C, Lasalle R. Malabsorption of bile acids in children with cystic fibrosis. New England Journal of Medicine 289: 1001–1005, 1973
Weiner IM, Mudge GH. Renal tubular mechanisms for excretion of organic acids and bases. American Journal of Medicine 36: 743–762, 1964
Weizman Z, Durie PR, Kopelman HR, Vesely SM, Forstner GG. Bile acid secretion in cystic fibrosis: evidence for a defect unrelated to fat malabsorption. Gut 27: 1043–1048, 1986
Weiler P. Cystic fibrosis. Practitioner 230: 539–545, 1986
White R, Woodward S, Leppert M, O’Connell P, Hoff M, et al. A closely linked genetic marker for cystic fibrosis. Nature 318: 382–384, 1985
Whiting PH, Barber HE, Petersen J. The effect of frusemide and piretanide on the renal clearance of gentamicin in man. British Journal of Clinical Pharmacology 12: 795–799, 1981
Winzor DJ, Ioannoni B, Reilly PEB. The nature of microsomal mono-oxygenasc inhibition by cimetidine. Biochemical Pharmacology 35: 2157–2161, 1986
Wood RE, Boat TF, Doershuk CF. Cystic fibrosis. American Reviews of Respiratory Diseases 113: 833–878, 1976
Woolf RA, Koup JR, Smith AL, Hilman BC, Goldman D, et al. Pharmacokinetics of high-dose azlocillin sodium in patients with cystic fibrosis. Clinical Pharmacy 4: 664–669, 1985
Yaffe SJ, Gerbracht LM, Mosovich LL, Mattar ME, Danish M. et al. Pharmacokinetics of methicillin in patients with cystic fibrosis. Journal of Infectious Diseases 135: 828–831, 1977
Zaske DE. Aminoglycosides. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, p. 210, Applied Therapeutics Inc., San Francisco, 1980
Ziemniak JA, Assael BM, Padoan R, Schenlag JJ. The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis: age related differences as compared to adults. European Journal of Clinical Pharmacology 26: 183–189, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Prandota, J. Clinical Pharmacology of Antibiotics and Other Drugs in Cystic Fibrosis. Drugs 35, 542–578 (1988). https://doi.org/10.2165/00003495-198835050-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198835050-00004